Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 241

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Criteria for the use of omics-based predictors in clinical trials

Open access
McShane, Lisa M., Cavenagh, Margaret M., Lively, Tracy G., Eberhard, David A., Bigbee, William L., Williams, P. Mickey, Mesirov, Jill P., Polley, Mei-Yin C., Kim, Kelly Y., Tricoli, James V., Taylor, Jeremy M. G., Shuman, Deborah J., Simon, Richard M., Doroshow, James H., Conley, Barbara A. · 2013 · Nature

Abstract

A checklist of criteria to determine the readiness of high-throughput ‘omics’-based tests for guiding patient therapy in clinical trials is discussed; the checklist, developed by the US National Cancer Institute in collaboration with additional scientists with relevant expertise, provides a framework to evaluate the strength of evidence for a test and outlines practical issues to consider before using the test in a clinical setting, with an aim to avoid premature advancement of omics-based tests in clinical trials. The potential of high-throughput 'omics' in clinical medicine is immense, with oncology leading the way in adopting these technologies. Working with researchers and clinicians from across the spectrum of these disciplines, the US National Cancer Institute (NCI) has developed a checklist of criteria that can be used to determine the readiness of omics-based tests for guiding patient care in clinical trials. Published in this Perspective feature, the checklist focuses on best practice in specimen preparation, assays, mathematical modelling, clinical trial design, ethics and more. It will be used to evaluate proposals for NCI-sponsored clinical trials in which omics tests guide therapy. The US National Cancer Institute (NCI), in collaboration with scientists representing multiple areas of expertise relevant to ‘omics’-based test development, has developed a checklist of criteria that can be used to determine the readiness of omics-based tests for guiding patient care in clinical trials. The checklist criteria cover issues relating to specimens, assays, mathematical modelling, clinical trial design, and ethical, legal and regulatory aspects. Funding bodies and journals are encouraged to consider the checklist, which they may find useful for assessing study quality and evidence strength. The checklist will be used to evaluate proposals for NCI-sponsored clinical trials in which omics tests will be used to guide therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature12564

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 241

Metadata

Authors
McShane, L. M., Cavenagh, M. M., Lively, T. G., Eberhard, D. A., Bigbee, W. L., Williams, P. M., Mesirov, J. P., Polley, M.-Y. C., Kim, K. Y., Tricoli, J. V., Taylor, J. M. G., Shuman, D. J., Simon, R. M., Doroshow, J. H., & Conley, B. A.
Venue
Nature
Published
2013-10-17
Volume
502
Issue
7471
Pages
317-320
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W1971061361
Cited by
241
References
2
FWCI
9.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Criteria for the use of omics-based predictors in clinical trials. https://app.cochat.ai/papers/10.1038/nature12564
The paper
McShane, L. M., Cavenagh, M. M., Lively, T. G., Eberhard, D. A., Bigbee, W. L., Williams, P. M., Mesirov, J. P., Polley, M.-Y. C., Kim, K. Y., Tricoli, J. V., Taylor, J. M. G., Shuman, D. J., Simon, R. M., Doroshow, J. H., & Conley, B. A. (2013). Criteria for the use of omics-based predictors in clinical trials. Nature. https://doi.org/10.1038/nature12564

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.